ArQule, Inc.

ArQule, Inc.

ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts. ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company’s product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).

Contact Details

Office Address

ArQule, Inc.
19 Presidential Way
Woburn, MA, USA 01801-5140
Phone: (781) 994-0300
Fax: (781) 376-6019


Chief Exec. Officer

Mr. Paolo Pucci

Chief Operating Officer

Mr. Peter S. Lawrence J.D.

Business Reviews for ArQule, Inc.

Related Companies